MEDCL — Medincell SA Share Price
0.000.00%
Last trade - 00:00- €318.79m
- €355.22m
- €9.89m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 138.75 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 29.39 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -69.68% | ||
| Return on Equity | n/a | ||
| Operating Margin | -197.01% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 1.44 | 2.85 | 8.19 | 4.09 | 9.89 | 14.78 | 50.13 | 8.96% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Medincell SA is a France-based manufacturer of biological products and pharmaceutical preparations. The Company is focused on the development of therapeutic solutions with worldwide access. The Company works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
Directors
- Anh Nguyen CSU
- Christophe Douat CMG
- Sabri Markabi VSU
- Jaime Arango CFO
- Franck Pouzache DHR
- Joel Richard MGB
- Philippe Guy IND
- Elisabeth Kogan IND
- Virginie Lleu IND
- Karine Lignel SUB (53)
- Last Annual
- March 31st, 2023
- Last Interim
- September 30th, 2023
- Incorporated
- November 22nd, 2002
- Public Since
- October 8th, 2018
- No. of Employees
- 138
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Euronext - Paris
- Shares in Issue
- 28,719,999
- Address
- 3 rue des Freres Lumiere, JACOU, 34830
- Web
- https://www.medincell.com/
- Phone
- +33 467021367
- Contact
- Louis-Victor Delouvrier
- Auditors
- PricewaterhouseCoopers Audit
Upcoming Events for MEDCL
Medincell SA Annual Shareholders Meeting
Similar to MEDCL
AB Science SA
Euronext - Paris
Advicenne SA
Euronext - Paris
Aelis Farma SA
Euronext - Paris
Boiron SA
Euronext - Paris
DBV Technologies SA
Euronext - Paris
FAQ
What is the Medincell SA share price?
As of Today at 19:14 UTC, shares in Medincell SA are trading at €11.10. This share price information is delayed by 15 minutes.
How has the Medincell SA share price performed this year?
Shares in Medincell SA last closed at €11.10 and the price had moved by +18.72% over the past 365 days. In terms of relative price strength the Medincell SA share price has outperformed the FTSE Global All Cap Index by +11.45% over the past year.
What are the analyst and broker recommendations for Medincell SA?
The overall consensus recommendation for Medincell SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Medincell SA dividend yield?
Medincell SA does not currently pay a dividend.
Does Medincell SA pay a dividend?
Medincell SA does not currently pay a dividend.
When does Medincell SA next pay dividends?
Medincell SA does not currently pay a dividend.
How do I buy Medincell SA shares?
To buy shares in Medincell SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Medincell SA?
As of the previous close price of €11.10, shares in Medincell SA had a market capitalisation of €318.79m.
Where are Medincell SA shares listed?
Here are the trading details for Medincell SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: MEDCL
What kind of share is Medincell SA?
Based on an overall assessment of its quality, value and momentum Medincell SA is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Medincell SA share price forecast for 2024?
The analyst consensus target price for shares in Medincell SA is €17.00. That is 53.15% above the last closing price of €11.10.
Analysts covering Medincell SA currently have a consensus Earnings Per Share (EPS) forecast of -€1.02 for the next financial year.
What is the trend in the Medincell SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medincell SA. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +58.29%.
As of the last closing price of €11.10, shares in Medincell SA were trading +50.91% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Medincell SA PE Ratio?
The Medincell SA PE ratio based on its reported earnings over the past 12 months is 138.75. The shares last closed at €11.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Medincell SA?
Medincell SA's management team is headed by:
- Anh Nguyen - CSU
- Christophe Douat - CMG
- Sabri Markabi - VSU
- Jaime Arango - CFO
- Franck Pouzache - DHR
- Joel Richard - MGB
- Philippe Guy - IND
- Elisabeth Kogan - IND
- Virginie Lleu - IND
- Karine Lignel - SUB